17.26 0.00 (0.00%)
After hours: 4:31PM EDT
|Bid||12.15 x 1100|
|Ask||0.00 x 4000|
|Day's Range||17.20 - 17.63|
|52 Week Range||12.89 - 19.94|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Ironwood Pharmaceuticals Inc. activist investor Alex Denner helped send shares higher by almost a third since announcing his intention last month to join the board. The drugmaker is less than two weeks from its highly anticipated annual meeting and Sarissa Capital Management has yet to file a final proxy soliciting shareholder votes for Denner’s nomination. "My sense of it is: A lot is going on behind the scenes," Berenberg’s Patrick Trucchio said, adding that the delay "seems odd." The agency representing Sarissa, D.F. King & Co., expects a definitive proxy to be filed, writes Trucchio, who has a buy rating on the stock and a Street-high price target.
Commercial stage biopharma company Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD )'s Linzess, which it markets along with Allergan plc (NYSE: AGN ) in the U.S., is a major revenue earner for the company. ...
Ironwood Pharmaceuticals (IRWD) misses estimates on both counts in the first quarter. The company will be separated into two entities for better management.
Alex Denner, a protege of Carl Icahn, is known for orchestrating sales of companies in which he invests — including some local biotechs.
It will leave Ironwood as a traditional drugmaker focused on selling medications for irritable bowel syndrome, gout and reflux disease, with the goal of earning regular profits from the revenue growth. The other company will be more akin to a biotech aiming to bring to market promising but unproven drugs for rare disorders, such as sickle cell disease.
Ironwood Pharmaceuticals plans to separate into two entities next year. Activist investor Alex Denner of Sarissa Capital has invested in the company and is seeking a seat on its board. Ironwood Pharmaceuticals' IRWD stock rose Tuesday after the company said it plans to separate next year, immediately establishing profitability for its commercial entity and separating some of its pipeline assets into another unit.
The Cambridge, Massachusetts-based company said it had a loss of 29 cents per share. Losses, adjusted for one-time gains and costs, came to 27 cents per share. The drugmaker posted revenue of $69.2 million ...
The 730-employee company said that both businesses would be publicly traded and headquartered in Cambridge.
Short interest is moderately high for IRWD with between 10 and 15% of shares outstanding currently on loan. The net inflows of $122 million over the last one-month into ETFs that hold IRWD are among the lowest of the last year and appear to be slowing.
Ironwood Pharmaceuticals told shareholders Monday that it's learned biotech activist investor Alex Denner of Sarissa Capital is seeking to join its board.
Ironwood Pharmaceuticals Inc’s (NASDAQ:IRWD): Ironwood Pharmaceuticals, Inc., a commercial biotechnology company, engages in the research, development, and commercialization of human therapeutic products. The US$2.14B market-cap company announced a latest lossRead More...
Short interest is moderately high for IRWD with between 10 and 15% of shares outstanding currently on loan. The net inflows of $277 million over the last one-month into ETFs that hold IRWD are not among the highest of the last year and have been slowing.
Short interest is moderately high for IRWD with between 10 and 15% of shares outstanding currently on loan. Over the last one-month, outflows of investor capital in ETFs holding IRWD totaled $348 million.
The Cambridge, Massachusetts-based company said it had net income of 8 cents per share. Losses, adjusted for non-recurring gains, came to 14 cents per share. The results exceeded Wall Street expectations. ...
For investors, increase in profitability and industry-beating performance can be essential considerations in an investment. Below, I will examine Ironwood Pharmaceuticals Inc’s (NASDAQ:IRWD) track record on a high level, toRead More...
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Ironwood Pharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to IRWD-US. Comparing the performance and risk of Ironwood Pharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)